Artivion Receives FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis

MT Newswires Live2024-12-10

Artivion (AORT) said Monday it has received a humanitarian device exemption from the US Food and Drug Administration, allowing the commercial distribution of its AMDS hybrid prosthesis device to treat acute DeBakey Type 1 aortic dissections.

Under HDE, the AMDS hybrid prosthesis will be available as a treatment for acute DeBakey Type 1 dissections in the presence of malperfusion, Artivion said. If its premarket approval application for the device is approved, the device may be used in all DeBakey Type 1 dissections, including those without malperfusion, the company added.

Artivion said the HDE helps position AMDS hybrid prosthesis for a broader commercial launch, letting the company obtain approvals from institutional review boards and hospital value analysis committees and starting the process of training surgeons to implant the device.

Artivion shares were down more than 3% in recent trading.

Price: 28.73, Change: -0.93, Percent Change: -3.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490722057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 00:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490722057","market":"sg","top_or_hot":-1,"title":"Artivion Receives FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AORT\">Artivion</a> (AORT) said Monday it has received a humanitarian device exemption from the US Food and Drug Administration, allowing the commercial distribution of its AMDS hybrid prosthesis device to treat acute DeBakey Type 1 aortic dissections.</p><p>Under HDE, the AMDS hybrid prosthesis will be available as a treatment for acute DeBakey Type 1 dissections in the presence of malperfusion, Artivion said. If its premarket approval application for the device is approved, the device may be used in all DeBakey Type 1 dissections, including those without malperfusion, the company added.</p><p>Artivion said the HDE helps position AMDS hybrid prosthesis for a broader commercial launch, letting the company obtain approvals from institutional review boards and hospital value analysis committees and starting the process of training surgeons to implant the device.</p><p>Artivion shares were down more than 3% in recent trading.</p><p>Price: 28.73, Change: -0.93, Percent Change: -3.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artivion Receives FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtivion Receives FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 00:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artivion (AORT) said Monday it has received a humanitarian device exemption from the US Food and Drug Administration, allowing the commercial distribution of its AMDS hybrid prosthesis device to treat...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0031619046.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490722057","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490722057","pubTimestamp":1733761304,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Artivion  said Monday it has received a humanitarian device exemption from the US Food and Drug Administration, allowing the commercial distribution of its AMDS hybrid prosthesis device to treat acute DeBakey Type 1 aortic dissections.Under HDE, the AMDS hybrid prosthesis will be available as a treatment for acute DeBakey Type 1 dissections in the presence of malperfusion, Artivion said. If its premarket approval application for the device is approved, the device may be used in all DeBakey Type 1 dissections, including those without malperfusion, the company added.Artivion said the HDE helps position AMDS hybrid prosthesis for a broader commercial launch, letting the company obtain approvals from institutional review boards and hospital value analysis committees and starting the process of training surgeons to implant the device.Artivion shares were down more than 3% in recent trading.Price: 28.73, Change: -0.93, Percent Change: -3.15","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","AMDS":"GRANITESHARES 1X SHORT AMD DAILY ETF","AORT":"Artivion","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"Artivion获得FDA AMDS混合假体人道主义器械豁免","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMDS":1,"AORT":1},"content_text":"Artivion (AORT) said Monday it has received a humanitarian device exemption from the US Food and Drug Administration, allowing the commercial distribution of its AMDS hybrid prosthesis device to treat acute DeBakey Type 1 aortic dissections.Under HDE, the AMDS hybrid prosthesis will be available as a treatment for acute DeBakey Type 1 dissections in the presence of malperfusion, Artivion said. If its premarket approval application for the device is approved, the device may be used in all DeBakey Type 1 dissections, including those without malperfusion, the company added.Artivion said the HDE helps position AMDS hybrid prosthesis for a broader commercial launch, letting the company obtain approvals from institutional review boards and hospital value analysis committees and starting the process of training surgeons to implant the device.Artivion shares were down more than 3% in recent trading.Price: 28.73, Change: -0.93, Percent Change: -3.15","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490722057"}